Burcon NutraScience (BU) Q4 2026 earnings summary

Executive summary

• Targeting a large, growing market for plant-based proteins, driven by consumer demand for better nutrition, health trends, and increased protein needs, including those influenced by GLP-1 medications.

• Transitioned from technology development to commercial execution, commissioning a production facility and achieving first commercial production and sales across pea, canola, and fava protein platforms.

• Robust sales pipeline with over 200 active projects and more than 30 active buyers, showing strong customer adoption and diversity.

• Completed a non-brokered private placement of convertible debentures for $4.0 million, with an additional $2.9 million raised after year-end.

• Extended the maturity date of a senior secured loan to December 17, 2026, and amended interest to 15% per annum.

Financial highlights

• Fiscal 2026 revenue reached CAD 2.3 million (or $2.3 million), a nearly sixfold (494%) increase year-over-year, driven by protein sales and contract manufacturing.

• Double-digit quarter-over-quarter revenue growth in both Q3 and Q4.

• Net loss was $14.3 million ($1.12 per share), compared to $8.3 million ($1.06 per share) in the prior year.

• General and administrative expenses decreased by 23% and R&D expenses by 65% year-over-year.

• As of March 31, 2026, cash was $1.0 million with negative working capital of $10.6 million.

Outlook and guidance

• Expectation of continued momentum and significant quarter-over-quarter revenue growth into fiscal 2027.

• Fiscal Q1 projected to deliver 50% quarter-on-quarter growth compared to the previous quarter.

• Commitment to achieving CAD 10 million in sales in calendar 2026 and positive operating cash flow.

• Management highlighted scalability of the commercialization platform and continued expansion of production capacity.

• Over 200 customer projects under evaluation, indicating a robust commercial pipeline.